dc.creatorVidal, René L.
dc.creatorMatus, Soledad
dc.creatorBargsted, Leslie
dc.creatorHetz Flores, Claudio
dc.date.accessioned2018-12-20T15:10:59Z
dc.date.available2018-12-20T15:10:59Z
dc.date.created2018-12-20T15:10:59Z
dc.date.issued2014
dc.identifierTrends in Pharmacological Sciences, Volumen 35, Issue 11, 2018, Pages 583-591
dc.identifier18733735
dc.identifier01656147
dc.identifier10.1016/j.tips.2014.09.002
dc.identifierhttps://repositorio.uchile.cl/handle/2250/158342
dc.description.abstract© 2014 Elsevier B.V. All rights reserved. The most prevalent neurodegenerative disorders involve protein misfolding and the aggregation of specific proteins. Autophagy is becoming an attractive target to treat neurodegenerative disorders through the selective degradation of abnormally folded proteins by the lysosomal pathway. However, accumulating evidence indicates that autophagy impairment at different regulatory steps may contribute to the neurodegenerative process. Thus, a complex scenario is emerging where autophagy may play a dual role in neurodegenerative diseases by causing the downstream effect of promoting the degradation of misfolded proteins and an upstream effect where its deregulation perturbs global proteostasis, contributing to disease progression. Challenges in the future development of therapeutic strategies to target the autophagy pathway are discussed.
dc.languageen
dc.publisherElsevier Ltd
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceTrends in Pharmacological Sciences
dc.subjectaggregation
dc.subjectautophagy
dc.subjectBeclin 1
dc.subjectmTOR
dc.subjectneurodegenerative disease
dc.subjectrapamycin
dc.titleTargeting autophagy in neurodegenerative diseases
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución